ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Regulation FD Disclosure

ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01.

Regulation FD Disclosure
Item 8.01. Other Items

Presentation relating to Abeona Therapeutics Inc. The
presentation is attached as Exhibit 99.1 and is incorporated
herein.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Presentation entitled Abeona Therapeutics
99.2 Press release dated February 17, 2017, entitled Abeona
Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA
Clinical Trial at the 13th Annual WORLDSymposium
2017


About ABEONA THERAPEUTICS INC. (NASDAQ:ABEO)

Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.

ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Recent Trading Information

ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) closed its last trading session down -0.15 at 6.00 with 611,021 shares trading hands.

An ad to help with our costs